Sarah Croessmann

2.5k total citations
26 papers, 492 citations indexed

About

Sarah Croessmann is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Sarah Croessmann has authored 26 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Cancer Research and 11 papers in Oncology. Recurrent topics in Sarah Croessmann's work include Cancer Genomics and Diagnostics (12 papers), HER2/EGFR in Cancer Research (6 papers) and Advanced Breast Cancer Therapies (5 papers). Sarah Croessmann is often cited by papers focused on Cancer Genomics and Diagnostics (12 papers), HER2/EGFR in Cancer Research (6 papers) and Advanced Breast Cancer Therapies (5 papers). Sarah Croessmann collaborates with scholars based in United States, Italy and Canada. Sarah Croessmann's co-authors include Ben Ho Park, Rory L. Cochran, Daniel J. Zabransky, Karen Cravero, Sarah C. Reed, Paula J. Hurley, Hong Yuen Wong, David Chu, Josh Lauring and Julia A. Beaver and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Clinical Cancer Research.

In The Last Decade

Sarah Croessmann

22 papers receiving 480 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Croessmann United States 13 239 219 217 136 68 26 492
Valentina Vysotskaia United States 9 185 0.8× 250 1.1× 172 0.8× 134 1.0× 89 1.3× 15 481
Rebecca Watters United States 12 139 0.6× 217 1.0× 232 1.1× 211 1.6× 38 0.6× 25 519
Maria Cardenas United States 6 198 0.8× 214 1.0× 266 1.2× 117 0.9× 48 0.7× 14 496
Sang-Hyun Song South Korea 14 125 0.5× 215 1.0× 512 2.4× 97 0.7× 53 0.8× 18 644
Betül T. Yesilyurt Belgium 8 140 0.6× 194 0.9× 184 0.8× 89 0.7× 71 1.0× 9 452
Soonweng Cho United States 14 213 0.9× 163 0.7× 415 1.9× 75 0.6× 45 0.7× 24 580
Matthew R. Strickland United States 8 74 0.3× 218 1.0× 251 1.2× 150 1.1× 39 0.6× 18 475
Catherine J. Kennedy Australia 13 119 0.5× 194 0.9× 234 1.1× 176 1.3× 39 0.6× 25 560
Daniela Kandioler-Eckersberger Austria 8 235 1.0× 389 1.8× 220 1.0× 81 0.6× 63 0.9× 11 583
Jonas Ecker Germany 7 102 0.4× 232 1.1× 291 1.3× 59 0.4× 49 0.7× 11 488

Countries citing papers authored by Sarah Croessmann

Since Specialization
Citations

This map shows the geographic impact of Sarah Croessmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Croessmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Croessmann more than expected).

Fields of papers citing papers by Sarah Croessmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Croessmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Croessmann. The network helps show where Sarah Croessmann may publish in the future.

Co-authorship network of co-authors of Sarah Croessmann

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Croessmann. A scholar is included among the top collaborators of Sarah Croessmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Croessmann. Sarah Croessmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yajing, Cosmin A. Bejan, Caitlyn Vlasschaert, et al.. (2025). Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 124(4). 1042–1050.
2.
Reed, Sarah C., Leo Y. Luo, Melinda E. Sanders, et al.. (2025). Clonal Hematopoiesis of Indeterminate Potential Influences Breast Cancer Outcomes in a Genotype-Specific Manner. Clinical Cancer Research. 31(22). 4707–4719.
3.
Reed, Sarah C., et al.. (2024). An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release. Communications Biology. 7(1). 441–441. 9 indexed citations
4.
Bellomo, Sara E., et al.. (2024). Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations. BMC Genomics. 25(1). 519–519. 2 indexed citations
5.
Reed, Sarah C., Sarah Croessmann, & Ben Ho Park. (2022). CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors. Clinical Cancer Research. 29(8). 1403–1411. 42 indexed citations
6.
Croessmann, Sarah, et al.. (2021). The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer. British Journal of Cancer. 125(6). 780–788. 22 indexed citations
7.
Croessmann, Sarah & Ben Ho Park. (2021). Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.. PubMed. 19(3). 155–161. 13 indexed citations
8.
Croessmann, Sarah, et al.. (2020). Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission. Journal of the National Comprehensive Cancer Network. 18(4). 375–379. 3 indexed citations
9.
Kyker‐Snowman, Kelly, Robert M. Hughes, Christopher L. Yankaskas, et al.. (2019). TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Research and Treatment. 179(3). 631–642. 15 indexed citations
10.
Croessmann, Sarah, John H. Fetting, Vered Stearns, et al.. (2019). Pathogenic Germline Variants in Patients With Metastatic Breast Cancer. JAMA Oncology. 5(10). 1506–1506. 6 indexed citations
11.
Sudhan, Dhivya R., Luis J. Schwarz, Ángel Guerrero‐Zotano, et al.. (2018). Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clinical Cancer Research. 25(2). 771–783. 26 indexed citations
12.
Croessmann, Sarah, Luigi Formisano, Lisa N. Kinch, et al.. (2018). Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. Clinical Cancer Research. 25(1). 277–289. 78 indexed citations
13.
Beierl, Katie, Christopher D. Gocke, Daniel J. Zabransky, et al.. (2017). Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component. Clinical Cancer Research. 23(16). 4875–4884. 29 indexed citations
14.
Croessmann, Sarah, Jonathan H. Sheehan, Kyung‐min Lee, et al.. (2017). PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors. Clinical Cancer Research. 24(6). 1426–1435. 27 indexed citations
15.
Croessmann, Sarah, Hong Yuen Wong, Daniel J. Zabransky, et al.. (2017). PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. Breast Cancer Research and Treatment. 162(3). 451–464. 17 indexed citations
16.
Schwarz, Luis J., Sarah Croessmann, Francesca Avogadri-Connors, et al.. (2017). Abstract 4818: Neratinib/fulvestrant but not fulvestrant alone maintain complete responses after treatment with trastuzumab/paclitaxel of mice bearing ER+/HER2+ xenografts. Cancer Research. 77(13_Supplement). 4818–4818. 3 indexed citations
17.
18.
Toro, Patricia Valda, Bracha Erlanger, Julia A. Beaver, et al.. (2015). Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clinical Biochemistry. 48(15). 993–998. 83 indexed citations
19.
Cochran, Rory L., Justin Cidado, Daniel J. Zabransky, et al.. (2015). Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. Oncotarget. 6(28). 25240–25251. 9 indexed citations
20.
Cochran, Rory L., Karen Cravero, David Chu, et al.. (2014). Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. Human Pathology. 45(7). 1546–1550. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valentina Vysotskaia Breakdown of academic impact, for papers by Rebecca Watters Breakdown of academic impact, for papers by Maria Cardenas Breakdown of academic impact, for papers by Sang-Hyun Song Breakdown of academic impact, for papers by Betül T. Yesilyurt Breakdown of academic impact, for papers by Soonweng Cho Breakdown of academic impact, for papers by Matthew R. Strickland Breakdown of academic impact, for papers by Catherine J. Kennedy Breakdown of academic impact, for papers by Daniela Kandioler-Eckersberger Breakdown of academic impact, for papers by Jonas Ecker
Rankless by CCL
2026